{"id":53223,"date":"2023-01-24T13:02:55","date_gmt":"2023-01-24T12:02:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/"},"modified":"2023-01-24T13:02:55","modified_gmt":"2023-01-24T12:02:55","slug":"inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/","title":{"rendered":"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference"},"content":{"rendered":"
\n

MONTREAL–(BUSINESS WIRE)–#CB1<\/a>–Inversago Pharma Inc. (\u201cInversago\u201d), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that Fran\u00e7ois Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023.\n<\/p>\n

<\/a><\/p>\n

\nFor additional information or to request a meeting with management, please contact conference representatives.\n<\/p>\n

\nAbout Inversago Pharma<\/b>\n<\/p>\n

\nInversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D \/ T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nGlenn S. Vraniak
\n
Chief Financial Officer
\n
Inversago Pharma Inc.
\n
info@inversago.com<\/a>\n<\/p>\n

\nMedia and Investors<\/b>
Argot Partners
\n
inversago@argotpartners.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONTREAL–(BUSINESS WIRE)–#CB1–Inversago Pharma Inc. (\u201cInversago\u201d), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that Fran\u00e7ois Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53223","6":"format-standard","7":"category-industry"},"yoast_head":"\nInversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTREAL–(BUSINESS WIRE)–#CB1–Inversago Pharma Inc. (\u201cInversago\u201d), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that Fran\u00e7ois Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-24T12:02:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230124005328\/en\/1693580\/21\/Inversago_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-01-24T12:02:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":203,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005328\\\/en\\\/1693580\\\/21\\\/Inversago_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/\",\"name\":\"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005328\\\/en\\\/1693580\\\/21\\\/Inversago_RGB.jpg\",\"datePublished\":\"2023-01-24T12:02:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005328\\\/en\\\/1693580\\\/21\\\/Inversago_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005328\\\/en\\\/1693580\\\/21\\\/Inversago_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference - Pharma Trend","og_description":"MONTREAL–(BUSINESS WIRE)–#CB1–Inversago Pharma Inc. (\u201cInversago\u201d), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that Fran\u00e7ois Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-24T12:02:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230124005328\/en\/1693580\/21\/Inversago_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference","datePublished":"2023-01-24T12:02:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/"},"wordCount":203,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230124005328\/en\/1693580\/21\/Inversago_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/","url":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/","name":"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230124005328\/en\/1693580\/21\/Inversago_RGB.jpg","datePublished":"2023-01-24T12:02:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230124005328\/en\/1693580\/21\/Inversago_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230124005328\/en\/1693580\/21\/Inversago_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/inversago-pharma-to-participate-at-the-2023-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53223"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53223\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}